• Molecular NameEnoxacin
  • SynonymNA
  • Weight320.324
  • Drugbank_IDDB00467
  • ACS_NO74011-58-8
  • Show 3D model
  • LogP (experiment)-1.02
  • LogP (predicted, AB/LogP v2.0)-0.73
  • pkaN/A
  • LogD (pH=7, predicted)-3.06
  • Solubility (experiment)3.43 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-2.61
  • LogSw (predicted, AB/LogsW2.0)0.53
  • Sw (mg/ml) (predicted, ACD/Labs)0.79
  • No.of HBond Donors2
  • No.of HBond Acceptors7
  • No.of Rotatable Bonds3
  • TPSA85.77
  • StatusFDA approved, US withdrawn
  • AdministrationN/A
  • PharmacologyAn oral broad-spectrum fluoroquinolone antibacterial agent used in the treatment of urinary tract infections and gonorrhea. Insomnia is a common adverse effect.
  • Absorption_valueN/A
  • Absorption (description)Rapidly absorbed following oral administration, with an absolute oral bioavailability of approximately 90%.
  • Caco_2N/A
  • Bioavailability87.0
  • Protein binding40.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic. Some isozymes of the cytochrome P-450 hepatic microsomal enzyme system are inhibited by enoxacin. After a single dose, greater than 40% was recovered in urine by 48 hours as unchanged drug.
  • Half life3~6 h (plasma)
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)LD50>2000